Mereo BioPharma Advances Alvelestat Toward Phase 3 Trial
LONDON, UK; SOLANA BEACH, California; and AHMEDABAD, India, August 11, 2026 Mereo BioPharma Group plc and Sentynl Therapeutics, Inc.,...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
LONDON, UK; SOLANA BEACH, California; and AHMEDABAD, India, August 11, 2026 Mereo BioPharma Group plc and Sentynl Therapeutics, Inc.,...
